An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients

Archives of Internal Medicine

Volumn 163, Issue 20, 2003, Pages 2518-2524

  Warkentin, Theodore E ^a,c   Roberts, Robin S ^a,b   Hirsh, Jack ^b   Kelton, John G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

^c HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTICOAGULANTS; AUTOANTIBODIES; CLINICAL TRIALS; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037610515     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.20.2518     Document Type: Article

References (33)

1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
2. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
3. Bunting RW, Doppelt SH, Lavine LS. Extreme thrombocytosis after orthopaedic surgery. J Bone Joint Surg Br. 1991;73:687-688.
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
5. Phelan BK. Heparin-associated thrombosis without thrombocytopenia. Ann Intern Med. 1983;99:637-638.
6. Hach-Wunderle V, Kainer K, Krug B, Müller-Berghaus G, Pötzsch B. Heparin-associated thrombosis despite normal platelet counts [letter]. Lancet. 1994;344:469-470.
7. Risch L, Pihan H, Zeller C, Huber AR. ET gets HIT-thrombocytotic heparin-induced thrombocytopenia in a patients with essential thrombocythemia (ET). Blood Coagul Fibrinolysis. 2000;11:663-667.
8. Klement D, Rammos S, von Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression: heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr. 1996;155:11-14.
9. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(suppl 5):9-16.
10. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545-551.
11. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
12. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
13. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
14. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
15. Matthews DE, Farewell VT. Using and Understanding Medical Statistics. 2nd ed. New York, NY: Karger; 1988:20-26.
16. Thomas DG. Exact confidence limits for the odds ratio in a 2 × 2. Appl Stat. 1971;20:105-110.
17. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981:143-146.
18. Metz CF. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283-298.
19. Hanley JA, McNeil BJ. The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
20. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
21. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet. 1982;2:1246-1249.
22. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925-230.
23. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
24. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets. 1999;10:319-326.
25. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
26. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol. 1998;35(suppl 5):17-25.
27. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
28. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
29. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530-2536.
30. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:231-269.
31. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
32. Kappers-Klunne MC, Boon DMS, Hop WCJ, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol. 1997;96:442-446.
33. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med. 2002;126:1415-1423.